Lonza Group AG
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Latest news
All LO3.F news ›Samsung Biologics Enters ADC Fill-Finish, Taking On Lonza and WuXi
Korea's first economic newspaper, established in 1960. Providing comprehensive coverage of Korean business, finance, technology, and economic news. Samsung Biologics (207940) will launch a drug product (DP) service for antibody-drug…
Qurient teams with Lonza to advance dual‑payload ADC platform using CDK7 drug
Deal opens ADC licensing path but hinges on client uptake and clinical proof It is not stopping at developing Mocasiclid as its own new drug, but is moving into a platform business to supply it as the payload (cytotoxic drug) for…
Lonza Group AG (LZAGY) Analyst/Investor Day Transcript
Lonza Group AG (LZAGY) Analyst/Investor Day October 14, 2026 12:00 PM EDTCompany ParticipantsWolfgang Wienand - Chief Executive OfficerPhilippe Deecke -... Lonza Group AG (LZAGY) Analyst/Investor Day October 14, 2026 12:00 PM EDT Wolfgang…
Lonza Capsugel to showcase plant-based Organicaps and advanced capsule technologies at SupplySide Global
Lonza Capsugel has announced it will be showcasing its hard empty capsules and technologies, dosage form expertise, specialised CDMO capabilities and science‑backed health ingredients at this year's SupplySide Global show Based at Booth…
Lipid Nanoparticle CDMO Market to Led by Evonik, Lonza and CordenPharma Drive Growth | SNS insider
openPR.com Lipid Nanoparticle CDMO Market to Led by Evonik, Lonza and CordenPharma Drive Growth | SNS insider Press release from: SNS Insider Pvt Ltd Lipid Nanoparticle CDMO Market Forecast Permanent link to this press release: You can…
Lonza expands dual-payload ADC technology offering through Qurient agreement
Manufacturing Chemist Dual-payload ADCs carry two different cytotoxic payloads on a single antibody, allowing them to attack each tumour cell through multiple mechanisms at the same time. The agreement includes Qurient’s highly selective…
Lonza sets new mid-term targets, confirms 2026 outlook
Lonza is seeking to become a pure-play drug manufacturer once it finalizes the planned sale of its Capsules & Health Ingredients business. Closing of the $3 billion deal, agreed with Lone Star Funds in March, is expected by the end of…
Qurient Shares Jump 8% on ADC Deal With Lonza
Lonza Unveils Platform Strategy at World ADC Qurient Positioned as Dual-Payload Solution Annette Sommer, who delivered the presentation, said current ADCs face limits from resistance and non-response caused by tumor heterogeneity. As a…
Key facts: Lonza (LONN) reorganized; CHI sale and CHF500m buyback
TradingView Key facts: Lonza (LONN) reorganized; CHI sale and CHF500m buyback - Lonza (LONN) reorganized into three business platforms, pivoted from capsules to a CDMO model, plans to sell CHI capsule unit to Lone Star in H2 2026 and a…
Qurient, Lonza to Jointly Commercialize Dual-Payload ADC Platform
Published 13 Oct.2026 08:06(KST) Qurient announced on October 13 that it had signed an agreement with Lonza to jointly commercialize its dual-payload ADC platform. Qurient company logo image. Qurient Under the agreement, Lonza will…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
contractpharma.com3
-
en.sedaily.com2
-
manufacturingchemist.com2
-
openpr.com2
-
thepharmaletter.com2
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 21 articles, not a forecast.